Abstract
Adoptive transfer of T cells engineered with chimeric antigen receptor (CAR) has been proved to have robust anti-tumor effects against hematological malignancies. However, problems about safety and efficacy, such as cytokine release syndrome (CRS), T cell exhaustion and antigen escape are still raised when patients are treated with CAR-T cells. Moreover, CAR-T therapy has limited applications in treating solid tumors, owing to inefficient infiltration and poor functional persistence of CAR-T cells and diverse immunosuppression in tumor microenvironment. In order to overcome these limitations and broad its applications, multiple controllable CAR-T technologies were exploited. In this article, we review the designs of intelligent controlled CAR-T technologies and the innovations that they bring about in recent years.
| Original language | English |
|---|---|
| Pages (from-to) | 606-609 |
| Number of pages | 4 |
| Journal | Synthetic and Systems Biotechnology |
| Volume | 8 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 2023 |
Keywords
- Autologous universal system
- Chimeric antigen receptor T
- On and off systems
- Safety and efficacy
- Synthetic notch system
- Tumor
Fingerprint
Dive into the research topics of 'Intelligent tunable CAR-T cell therapy leads the new trend'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver